Given that CD97 activates ERK, protein kinase B/Akt, or RhoA signaling pathways in prostate cancer cells, researchers further explored whether the binding of CD55 to CD97 could activate the same signaling pathways in leukocytes. Here, ADGRE2 is linked to prostate carcinoma.